A drug strategy targeting heat shock protein 90 to combat metastatic, p53 mutant ovarian cancer.

Project Information

GANNET53

Grant agreement ID: 602602

Project closed

Start date 1 October 2013

End date 31 December 2020

Funded under

• Specific Programme "Cooperation": Health

Total cost

€ 7 752 628,79

EU contribution

€ 5 994 072,00

Coordinated by

MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria